is expected to grow at a rapid rate of over 6% during the forecast period.
According to the company, REBINYN is indicated for on-demand treatment and control of bleeding episodes and the perioperative management of bleeding in adults and children with hemophilia B
Visit Hemophilia Treatment Market by Drug Type (Antifibrinolytic Agents, Desmopressin, Plasma Derived Coagulation Factor Concentrates - Factor VIII, Factor IX, Combination, Recombinant Coagulation Factor Concentrates - Factor VIII, Factor IX, Combination), Indication Type (Acquired Hemophilia, Hemophilia A, Hemophilia B
, Hemophilia C), and Distribution Channel (E-commerce, Hospital Pharmacies, Retail Pharmacies) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/hemophilia-treatment-market/
In this case report, the difficulties in treatment of an infant with severe hemophilia B
who developed antibody and allergic reaction against FIX treatment have been discussed.
* Early identification of canine hemophilia A, hemophilia B
and von Willebrand disease (VWD), a severe bleeding defect.
INTRODUCTION: The X-linked inherited coagulation disorders, hemophilia A (Factor VIII deficiency) and hemophilia B
(factor IX deficiency), together with Von Willebrand disease comprise 95 to 97 percent of all the inherited deficiencies of coagulation factors.1, 2 Both factors take part in the intrinsic pathway of blood coagulation and affected individuals have severe, moderate and mild forms of disease, defined by factor plasma levels of <1%, 2-5%, and 6-40%.respectively.
IB1001 is an intravenous recombinant Factor IX (rFIX) being developed for the treatment and prevention of bleeding episodes in hemophilia B
. The IB1001 development program includes pharmacokinetic, safety, and efficacy data from a Phase III trial in people with hemophilia B
Hemophilias A and B are X-linked genetic disorders; hemophilia A is due to deficiency of clotting factor VIII, while hemophilia B
is due to deficiency of clotting factor IX.
Most patients with hemophilia A are dependent on factor VIII replacement therapy, while patients with hemophilia B
are dependent on factor IX replacement therapy.
Arthropathy was the most frequently developing complication in patients 10 (100%) of severe Hemophilia B
. Post circumcision bleeding was found to be the most common first episode of bleeding in patients of haemophilia B 29 (64.4%).
Patients with hemophilia B
lack a protein known as factor IX.